• Bridgebio Oncology Therapeutics posted a net loss of USD 42.1 million, widening from USD 22.1 million a year earlier.
• R&D expense more than doubled to USD 39.8 million, while G&A expense climbed to USD 6.4 million as standalone operations ramped following de-SPAC.
• Cash, cash equivalents, and marketable securities totaled USD 388.9 million, with runway expected to fund operations into 2028.
• Pipeline update flagged a 65% objective response rate for BBO-8520 monotherapy in KRASG12C NSCLC, a partial response with 56% tumor reduction for BBO-11818 in pancreatic cancer, and full target engagement without hyperglycemia for BBO-10203.
• Updated clinical data across all three programs are expected in second half of 2026, with internal combination studies advancing during 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bridgebio Oncology Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605121703PRIMZONEFULLFEED9718960) on May 12, 2026, and is solely responsible for the information contained therein.